other companies: Industrial approvals generally do not specify separate capacity of each and every formulation and pack. Details of production and sales turn over of formulation are not monitored in this Ministry.

(f) Both the companies referred to in befrs of the Sub-Committee of Drugs Priameters of Drug Policy of 1978.

Sub Committee of drugs price review Committee

2816. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 978 given in the Rajya Sabha on 25th November, 1985 and state:

(a) what are the names of the members of the Sub-Committee of Drugs Prices Review Committee constituted by Government along with department each represents;

(b) what role is being played by each member and how many of them are costing experts or qualified;

(c) whether it is a fact that the nominee of his Ministry is deciding authority both at Sub-Committee as well as at departmental level;

(d) if so, what are the details thereof;

(e) what are the reasons for not verifying the purchase or procured price of each bulk drug of each formulator and how far fixing the formulation price based on notified price helps the consumer to get the medicines at fair price; and

(f) what is the justification in not fixing the formulations prices based on purchase price of bulk drug?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Director (Cost), DICP. Member (Finance) BICP, nominees of this Departments and representatives of DGTD and DGHS are Members of the Sub-Committee of Drugs Prices Review Committee.

(b) The Member Secretary of the Sub-Committee is a qualified Cost Accountant. The other members have expertise in finance, pharmacy and production processes.

(c) No, ir. The decisions of the Sub-Committee are collective decisions.

(d) Does not arise.

(e) and (f) The formulation prices are fixed based on relevant factors including the notified prices, purchase prices and landed prices of bulk drugs.

Formulations containing pentothol sodium

2817. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 983 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) whether it is a fact that Pentothol Sodium comes under Category III of DPCO, 1979;

(b) whether it is a fact that it goes into the production of Vitamin formulations;

(c) if so, what are the names of formulations being produced by Abbot containing Pentothol Sodium along with prices fixed for each pack and strength as well as their selling price of each product;

(d) whether it is a fact that Abbot was licensed to produce bulk drugs earlier to this licence;

(e) if so, what are the details thereof and whether that licence was implemented;

(f) if not, what are the reasons thereof;

(g) what are the details of exports of Rupees forty two lacs by Abbott in 1984 along with name of each formulation, composition, quantity and value of each; and

(h) what is the price fixed for Pentothol Sodium and whether it was based on Abbots cost of production?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) No, Sir.

(c) M/s. Abbott Laboratories are selling the forumulations of this drug under the name of Pentothol Sodium Injection at the approved price of 0.5 gm. vital at Rs. 5.08 and for 1 gm. vial at Rs. 8.52.

(d) to (f) Details of industrial licences obtained by M/s. Abbott Laboratories earlier in 1976 for different bulk drugs are given below:—

Sl. No.	Name of the Bulk Drug	Licensed quantity
1.	Gibberallic Acid	365·00 Kgs.
2.	Erythromycin .	4·00 tonnes
3.	Thiopentone Sodium	1000·00 Kgs.

As the party did not implement the licence the same was cancelled on 31st January, 1979.

(g) Information to the extent available is already given in reply to Rajya Sabha Unstarred Question No. 2199 answered on 9th December, 1985.

(h) M/s. Abbott Laboratories have recently applied for fixation of price of Pentothol Sodium.

Import of Drugs for sale

2818. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 977 given in the Rajya Sabha on 25th November 85 and state:

(a) whether it is a fact that Gentamycin Sulphate; Pseduo Ephedrine Hcl and Pyramethamina were imported for sale during 1981-82, 1982-83 and 1983-84;

(b) if so, what was the quantity imported by each company for sale during these years, year-wise and what was the price fixed for each drug for sale to others during each year;

(c) whether Government monitors the sale of those drugs;

(d) if so, what is the system adopted by Government and if not, then how Government could ensure that these drugs have been sold at fixed prices;

(e) whether Government have issued any notice to any importer who imported bulk drugs for sale and selling those drugs without obtaining the price fixation order; and

(f) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a), (b), (e) and (f) Details to the extent available would be collected and laid on the Table of the House.

(c) No Sir.

(d) As and when specific instances come to the notice of the Government, action is taken.

Shortage of PAS and its salts

2819. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to refer to the answer to unstarred Question 982 given in the Rajya Sabha on 25th November, 1985 and state:

(a) whether it is a fact that there is a shortage of PAS and its salts as well as Thiacetazone;

(b) names of drug companies which are licensed to produce these drugs, licenced capacity and production of each drug during the last three years, year-wise;

(c) whether it is a fact that drug companies are not interested to produce essential bulk drugs falling under category I and II;

(d) names of companies who are licensed to produce bulk drugs falling under category I and II along with licensed